Live Breaking News & Updates on Clinical trial protocol

Stay informed with the latest breaking news from Clinical trial protocol on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Clinical trial protocol and stay connected to the pulse of your community

ICH updates Good Clinical Practice Guideline

ICH E6(R3) continues to advance standards governing conduct of clinical trials

Helsinki , Eteläuomen-läi , Finland , International-council-for-harmonization , Editorial-article , International-council , Good-clinical-practice-guideline , Clinical-practice , Clinical-studies , Institutional-review , Independent-ethics-committees

ICH updates Good Clinical Practice Guideline

ICH E6(R3) continues to advance standards governing conduct of clinical trials

Helsinki , Eteläuomen-läi , Finland , International-council-for-harmonization , Editorial-article , International-council , Good-clinical-practice-guideline , Clinical-practice , Clinical-studies , Institutional-review , Independent-ethics-committees

Inclusion of 65+ age in JE vax trial urged

The plan is to develop an advanced version of JE vaccine that can cover a larger chunk of the population.

China , Telangana , Andhra-pradesh , India , Odisha , Orissa , Chhattisgarh , Pune , Maharashtra , Japan , Karnataka , Bharat

Novartis provides update on Phase III CANOPY-A study

Phase III CANOPY-A trial did not meet primary endpoint of disease-free survival in patients with stages II-IIIA and IIIB completely resected non-small...

United-states , America , American , Isabella-zinck , Jeff-legos , Veronique-boissonnas , Nicole-zinsli-somm , Biochim-biophys-acta , Samir-shah , Julie-masow , Parag-mahanti , Sloan-simpson

Novartis provides update on Phase III CANOPY-A study evaluating canakinumab as adjuvant treatment in non-small cell lung cancer | Antibodies

Novartis provides update on Phase III CANOPY-A study evaluating canakinumab as adjuvant treatment in non-small cell lung cancer

United-states , American , Biochim-biophys-acta , Jeff-legos , Global-head-of-oncology-hematology-development , American-joint-committee-on-cancer , World-health-organization , American-cancer-society , Union-for-international-cancer-control , Novartis , Switzerlandi-august , Executive-vice-president

Protocol for 3 COVID-19 vaccine brands to be used in WHO Solidarity Vaccine Trial now under FDA's review – Manila Bulletin

The Department of Science and Technology (DOST) said Thursday, Aug. 12, that the clinical trial protocol and other related documents for the three coronavirus disease (COVID-19) vaccines that will be used in the World Health Organization’s (WHO) Solidarity Vaccine Trial (SVT) are now being reviewed

Manila , Philippines , Pasay-city , Pasay , Taguig-city , City-of-taguig , San-juan-city , City-of-san-juan , Metro-manila , Philippines-general- , Paranaque-city , City-of-paranaque

WPD Pharmaceuticals to Attend the 10th Congress of the Polish Society of Pediatric Oncology and Hematology and Present Assumption of the Phase 1 Study with Berubicin in Pediatric Malignant Gliomas

Share:
WPD Pharmaceuticals Inc. (CSE:WBIO)(FSE: 8SV1) (the "
Company" or "
WPD") a clinical-stage pharmaceutical company, is pleased to announce that it will attend the 10
th Annual Congress of the Polish Society of Pediatric Oncology and Hematology to be held on May 6-8, 2021.
During the Congress, WPD will present the key assumptions of the WPD-201P Clinical Trial Protocol, which is planned to start in Q2 2021, as a part of the research project: "New approach to glioblastoma treatment addressing the critical unmet medical need", granted by National Research and Development Center ("
NRDC") and co-financed by the European Union, under the Smart Growth Operational Program 2014-2020.

Texas , United-states , New-york , United-kingdom , Canada , Poland , Russia , Vancouver , British-columbia , Polish , Canadian , British

Novartis Pharma AG: Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer

Novartis Pharma AG: Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer
1
non-small cell lung cancer
2,3
help
1 beta (IL-1ß) in pro-tumor inflammation i
n lung cancer, with multiple clinical trials investigating
canakinumab in
2
-5
Basel, March 9, 2021 - Novartis announced today the Phase III CANOPY-2 study evaluating canakinumab (ACZ885), an inhibitor of interleukin-1beta (IL-1ß), in combination with the chemotherapy agent docetaxel, did not meet its primary endpoint of overall survival (OS)
1. The trial was conducted among 237 adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed while on or after previous platinum-based chemotherapy and PD-(L)1 inhibitor immunotherapy

Thuren , Brandenburg , Germany , United-states , America , American , Isabella-zinck , Thomas-hungerbuehler , Samir-shah , Mary-curtin-creaser , Biochim-biophys-acta , Julie-masow

Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer

19. More people die of lung cancer every year than any other cancer type
11. Novartis is committed to developing best-in-class treatments for lung cancer patients around the world. With a focus on both targeted, personalized medicine and the role of newer, immuno-oncology therapies, the lung cancer drug development program at Novartis is among the most robust in the industry. With research activities informed by long-term relationships with leading lung cancer thought leaders and patient advocates, Novartis is focused on reimagining the treatment of lung cancer.
Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “potentially,” “can,” “will,” “expected,” “committed,” “evaluating,” “continue,” “ongoing,” “approximately,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for canakinumab, either alone or in combination with docetaxel or pembrolizumab, or regarding potential future revenues from canakinumab, either alone or in combination with docetaxel or pembrolizumab. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that canakinumab, either alone or in combination with docetaxel or pembrolizumab will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that canakinumab, either alone or in combination with docetaxel or pembrolizumab, separately or in combination, will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

United-states , America , American , Isabella-zinck , Thomas-hungerbuehler , Samir-shah , Mary-curtin-creaser , Biochim-biophys-acta , Julie-masow , Sloan-simpson , John-tsai , Global-oncology-communications

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.

Prostate-cancer-clinical-trials-working-group , Englj-med , Advanced-prostate-cancer-consensus-conference , Nucl-med , Genitourin-cancer , Clinical-trial-protocol , Clin-oncol , Urol-oncol , ப்ராஸ்டேட்-புற்றுநோய்-மருத்துவ-சோதனைகள்-வேலை-குழு , மருத்துவ-சோதனை-ப்ரோடொகால் ,